Heart failure (HF) is a life-threatening disease in which the heart cannot pump enough blood to the body. Affecting approximately 64 million people worldwide (at least a large proportion of these patients have reduced ejection fraction), heart failure is a chronic, degenerative disease in which half of all patients will die within five years of diagnosis. Heart failure remains as deadly as the most common form of cancer. Heart failure is the leading cause of hospitalization for patients over 65 years of age and represents a significant clinical and economic burden. Today we take a look at new drugs in the field of heart failure in recent years. 1. dagliflozin Dagliflozin tablets were actually originally approved by the FDA in 2014 in combination with diet and exercise for improving glycemic control in patients with type 2 diabetes and were approved for marketing in China in March 2017. While initially used as a glucose-lowering drug to control diabetes, it helps patients excrete excess glucose from the urine. In addition to lowering sugar, the drug has the added benefit of weight loss and lowering blood pressure. And with increased use found good therapeutic effects for heart failure. On May 5, the U.S. Food and Drug Administration (FDA) announced that it has approved Dagliflozin tablets for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure who have reduced ejection fraction. Several clinical trials have demonstrated that dagliflozin tablets can improve survival and reduce the need for hospitalization in adults with heart failure with reduced ejection fraction. Currently used primarily on a diet and exercise basis, this product can be used as monotherapy to improve glycemic control in adult patients with type 2 diabetes. and adult patients with heart failure with reduced ejection fraction (the domestic indication has not yet been updated). It is contraindicated in patients with severe renal impairment, renal failure, end-stage renal disease or who require dialysis. Possible adverse reactions: . Hypotension, . ketoacidosis, . Acute kidney injury and renal impairment, . urinary sepsis and pyelonephritis, hypoglycemia due to combination with insulin and insulinotropic agents, . Genital fungal infections, . Elevated low-density lipoprotein cholesterol (LDL-C). 2.Sacubitril valsartan sodium tablets In the development of heart failure drugs, sacubitril valsartan sodium tablets gradually emerged as a new hope for heart failure treatment. Sacubitril valsartan sodium tablets significantly reduce the risk of cardiovascular death, the risk of heart failure hospitalization, and the risk of all-cause death in heart failure patients, and significantly improve the symptoms and quality of life of heart failure patients. In view of its excellent clinical benefits, Sacubitril valsartan sodium tablets were rapidly recommended by international authoritative guidelines, and new editions of European, American and Chinese heart failure treatment guidelines have made Class I recommendations for Sacubitril valsartan sodium tablets. The efficacy and safety of Sacubitril valsartan sodium tablets in the treatment of heart failure with reduced ejection fraction is the first cornerstone of heart failure treatment to date that covers both acute and chronic, inpatient and outpatient settings. Sacubitril valsartan sodium tablets are used in adult patients with chronic heart failure (NYHA class II-IV, LVEF ≤ 40%) with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure. Caution when taking the drug may result in the following clinically significant adverse reactions: angioedema, hypotension, impaired renal function, hyperkalemia. Combination with ACEI is prohibited. This product must be taken only after 36 hours of discontinuation of ACEI therapy. Contraindicated in patients with a prior history of angioedema associated with ACEI or ARB therapy. Contraindicated in patients with hereditary or idiopathic angioedema. Combination with aliskiren is contraindicated in patients with type 2 diabetes mellitus. Contraindicated in severe hepatic impairment, biliary cirrhosis and cholestasis. Contraindicated in patients with mid- and late-term pregnancy.